Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Statera Biopharma, Inc. (STAB : NSDQ)
 
 • Company Description   
Statera BioPharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Statera BioPharma, formerly known as Cytocom Inc., is based in FORT COLLINS, Colo.

Number of Employees: 6

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.24 Daily Weekly Monthly
20 Day Moving Average: 15,730,405 shares
Shares Outstanding: 37.47 (millions)
Market Capitalization: $9.06 (millions)
Beta: 1.16
52 Week High: $7.10
52 Week Low: $0.20
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.20% -10.37%
12 Week -70.65% -68.16%
Year To Date -89.49% -87.50%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2537 RESEARCH BOULEVARD SUITE 201
-
FORT COLLINS,CO 80526
USA
ph: 888-613-8802
fax: 716-849-6820
nichol.ochsner@staterabiopharma.com http://www.staterabiopharma.com
 
 • General Corporate Information   
Officers
Christopher Zosh - Vice President of Finance
Lea Verny - Director
Randy Saluck - Director
Alexander Andryushechkin - Director
Anna Evdokimova - Director

Peer Information
Statera Biopharma, Inc. (CORR.)
Statera Biopharma, Inc. (RSPI)
Statera Biopharma, Inc. (CGXP)
Statera Biopharma, Inc. (BGEN)
Statera Biopharma, Inc. (GTBP)
Statera Biopharma, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 857561104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 37.47
Most Recent Split Date: 1.00 (0.05:1)
Beta: 1.16
Market Capitalization: $9.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.10
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -1,075.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -37.36
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -30.13
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - 1.31
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - 1.31
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -3,465.23
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - 2.31
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - 0.17
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - 14.83
 

Powered by Zacks Investment Research ©